Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Pertuzumab Biosimilar Shows Promise in HER2-Positive Breast Cancer Treatment

December 9th 2024

By Skylar Jeremias

Article

The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in neoadjuvant treatment of HER2-positive, ER/PR-negative early or locally advanced breast cancer, offering a cost-effective alternative with comparable clinical outcomes.

AI-Powered Solutions for Streamlining Biosimilar Prescribing and Monitoring

December 8th 2024

By Skylar Jeremias

Video

Steve Pickette, PharmD, BCPS, emphasizes that AI can streamline prescribing and formulary management for biosimilars and generics, enhance provider engagement, and improve pharmacovigilance by tracking adoption rates and identifying potential issues.

Similar Persistence Rates Between Adalimumab New Starts, Switched Patients

December 7th 2024

By Deana Ferreri, PhD

Article

A French real-world study found that the adalimumab biosimilar SB5 was effective in treating rheumatic or gastrointestinal immune-mediated inflammatory diseases, showing no loss of disease control in switched patients and similar persistence rates between naive and switched groups.

The Top 5 Biosimilar Articles for the Week of December 2

December 6th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of December 2, 2024.

Switching to Rituximab Biosimilars Is Safe, Effective for Patients With Oncohematological Diseases

December 5th 2024

By Cameron Santoro

Article

Patients with oncohematological diseases switching to rituximab biosimilars experienced similar safety and efficacy, highlighting biosimilars' potential for cost-effective treatment across various medical conditions.

Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts

December 4th 2024

By Skylar Jeremias

Article

Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.

Cost and Efficacy Insights on Infliximab Biosimilars in Pediatric Uveitis

December 3rd 2024

By Skylar Jeremias

Article

The study highlights the safety, efficacy, and cost benefits of infliximab biosimilars in managing pediatric noninfectious uveitis, showing fewer disease flares and reduced costs compared with reference infliximab, as well as the influence of insurance mandates on treatment decisions.

FDA Approves Biocon Biologics Ustekinumab Biosimilar, Yesintek

December 2nd 2024

By Skylar Jeremias

Article

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology conditions, including psoriatic arthritis and inflammatory bowel disease.

Perceptions of Biosimilar Switching Among Veterans With IBD

December 2nd 2024

By Deana Ferreri, PhD

Article

Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in biosimilar switching, favoring delayed switching for severe cases and greater patient control.

Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition

December 1st 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.